{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:47:54Z","timestamp":1784933274085,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T00:00:00Z","timestamp":1488412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1038\/jhh.2017.8","type":"journal-article","created":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T10:21:06Z","timestamp":1488450066000},"page":"376-381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Protective effects of nebivolol from oxidative stress to prevent hypertension-related target organ damage"],"prefix":"10.1038","volume":"31","author":[{"given":"A","family":"Coats","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,2]]},"reference":[{"key":"BFjhh20178_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1471-2296-12-75","volume":"12","author":"A Papazafiropoulou","year":"2011","unstructured":"Papazafiropoulou A, Skliros E, Sotiropoulos A, Papafragos C, Gikas A, Apostolou O et al. Prevalence of target organ damage in hypertensive subjects attending primary care: C.V.P.C. study (epidemiological cardio-vascular study in primary care). BMC Fam Pract 2011; 12: 75.","journal-title":"BMC Fam Pract"},{"key":"BFjhh20178_CR2","first-page":"866","volume":"107","author":"RE Schmieder","year":"2010","unstructured":"Schmieder RE . End organ damage in hypertension. Dtsch Arztebl Int 2010; 107: 866\u2013873.","journal-title":"Dtsch Arztebl Int"},{"key":"BFjhh20178_CR3","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","volume":"31","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, Red\u00f3n J, Zanchetti A, B\u00f6hm M et al. 2013 ESH\/ESC Guidelines for the Management of Arterial Hypertension. J Hypertens 2013; 31: 1281\u20131357.","journal-title":"J Hypertens"},{"key":"BFjhh20178_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/hr.2010.201","volume":"34","author":"RM Touyz","year":"2011","unstructured":"Touyz RM, Briones AM . Reactive oxygen species and vascular biology: implications in human hypertension. Hypertens Res 2011; 34: 5\u201314.","journal-title":"Hypertens Res"},{"key":"BFjhh20178_CR5","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3389\/fphys.2013.00321","volume":"4","author":"V Conti","year":"2013","unstructured":"Conti V, Russomanno G, Corbi G, Izzo V, Vecchione C, Filippelli A . Adrenoreceptors and nitric oxide in the cardiovascular system. Front Physiol 2013; 4: 321.","journal-title":"Front Physiol"},{"issue":"e-Supplement A","key":"BFjhh20178_CR6","first-page":"26.62","volume":"28","author":"J Segura","year":"2010","unstructured":"Segura J, De La Sierra A, Fernandez S, Ruilope LM . High prevalence of target organ damage in hypertensive and prehypertensive patients with associated cardiovascular risk factors. J Hypertens 2010; 28 (e-Supplement A):26.62.","journal-title":"J Hypertens"},{"key":"BFjhh20178_CR7","unstructured":"National Clinical Guideline Centre UK. The Clinical Management of Primary Hypertension in Adults. The National Clinical Guideline Centre at The Royal College of Physicians: London, UK, 2011."},{"key":"BFjhh20178_CR8","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/00003495-199957040-00011","volume":"57","author":"W McNeely","year":"1999","unstructured":"McNeely W, Goa KL . Nebivolol in the management of essential hypertension: a review. Drugs 1999; 57: 633\u2013651.","journal-title":"Drugs"},{"key":"BFjhh20178_CR9","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1097\/00005344-199306000-00002","volume":"21","author":"LM Van Bortel","year":"1993","unstructured":"Van Bortel LM, Breed JG, Joosten J, Kragten JA, Lustermans FA, Mooij JM . Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life. J Cardiovasc Pharmacol 1993; 21: 856\u2013862.","journal-title":"J Cardiovasc Pharmacol"},{"key":"BFjhh20178_CR10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0011-393X(01)80056-4","volume":"62","author":"TJ Cleophas","year":"2001","unstructured":"Cleophas TJ, Grabowsky I, Niemeyer MG, M\u00e4kel WN, van der Wall EE . Long-term efficacy of nebivolol monotherapy in patients with hypertension. Curr Ther Res 2001; 62: 451\u2013461.","journal-title":"Curr Ther Res"},{"key":"BFjhh20178_CR11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/01.mjt.0000149923.39085.44","volume":"13","author":"TJ Cleophas","year":"2006","unstructured":"Cleophas TJ, Agrawal R, Lichtenthal A, M\u00e4kel W, Fici F . Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients. Am J Ther 2006; 13: 192\u2013197.","journal-title":"Am J Ther"},{"key":"BFjhh20178_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2165\/00129784-200808010-00005","volume":"8","author":"LM Van Bortel","year":"2008","unstructured":"Van Bortel LM, Fici F, Mascagni F . Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. Am J Cardiovasc Drugs 2008; 8: 35\u201344.","journal-title":"Am J Cardiovasc Drugs"},{"key":"BFjhh20178_CR13","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2165\/00003495-200666100-00007","volume":"66","author":"MD Moen","year":"2006","unstructured":"Moen MD, Wagstaff AJ . Nebivolol: a review of its use in the management of hypertension and chronic heart failure. Drugs 2006; 66: 1389\u20131409; discussion 1410.","journal-title":"Drugs"},{"key":"BFjhh20178_CR14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2147\/vhrm.2006.2.3.303","volume":"2","author":"R Weiss","year":"2006","unstructured":"Weiss R . Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation. Vasc Health Risk Manag 2006; 2: 303\u2013308.","journal-title":"Vasc Health Risk Manag"},{"key":"BFjhh20178_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/VHRM.S20669","volume":"8","author":"JE Toblli","year":"2012","unstructured":"Toblli JE, DiGennaro F, Giani JF, Dominici FP . Nebivolol: impact on cardiac and endothelial function and clinical utility. Vasc Health Risk Manag 2012; 8: 151\u2013160.","journal-title":"Vasc Health Risk Manag"},{"key":"BFjhh20178_CR16","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S0002-9149(03)00645-3","volume":"92","author":"O Kamp","year":"2003","unstructured":"Kamp O, Sieswerda GT, Visser CA . Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol 2003; 92: 344\u2013348.","journal-title":"Am J Cardiol"},{"key":"BFjhh20178_CR17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/01.hjh.0000160216.86597.ff","volume":"23","author":"A Fratta Pasini","year":"2005","unstructured":"Fratta Pasini A, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005; 23: 589\u2013596.","journal-title":"J Hypertens"},{"key":"BFjhh20178_CR18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1177\/1753944709104496","volume":"3","author":"A Maffei","year":"2009","unstructured":"Maffei A, Lembo G . Nitric oxide mechanisms of nebivolol. Ther Adv Cardiovasc Dis 2009; 3: 317\u2013327.","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"BFjhh20178_CR19","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ejheart.2004.10.015","volume":"7","author":"I Edes","year":"2005","unstructured":"Edes I, Gasior Z, Wita K . Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. Eur J Heart Fail 2005; 7: 631\u2013639.","journal-title":"Eur J Heart Fail"},{"key":"BFjhh20178_CR20","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1093\/eurjhf\/hfp104","volume":"11","author":"A Cohen-Solal","year":"2009","unstructured":"Cohen-Solal A, Kotecha D, van Veldhuisen DJ, Babalis D, B\u00f6hm M, Coats AJ et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. Eur J Heart Fail 2009; 11: 872\u2013880.","journal-title":"Eur J Heart Fail"},{"key":"BFjhh20178_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/hrt.2010.207365","volume":"97","author":"G Ambrosio","year":"2011","unstructured":"Ambrosio G, Flather MD, Bohm M, Cohen-Solal A, Murrone A, Mascagni F et al. Beta-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure. Heart 2011; 97: 209\u2013214.","journal-title":"Heart"},{"key":"BFjhh20178_CR22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.5830\/CVJA-2011-046","volume":"23","author":"SM Aksoy","year":"2012","unstructured":"Aksoy SM, Cay S, Cagirci G, Sen N . Nebivolol therapy improves QTc and QTcd parameters in heart failure patients. Cardiovasc J Afr 2012; 23: 191\u2013193.","journal-title":"Cardiovasc J Afr"},{"key":"BFjhh20178_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/BF03258269","volume":"3","author":"A Cherchi","year":"1991","unstructured":"Cherchi A, Lai C, Pirisi R, Onnis E . Antianginal and anti-ischaemic activity of nebivolol in stable angina of effort. Drug Investig 1991; 3(Suppl 1): 86\u201396.","journal-title":"Drug Investig"},{"key":"BFjhh20178_CR24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4103\/0253-7613.96349","volume":"44","author":"R Soanker","year":"2012","unstructured":"Soanker R, Naidu MUR, Raju SB, Prasad AK, Rao TRK . Effect of beta-1-blocker, nebivolol, on central aortic pressure and arterial stiffness in patients with essential hypertension. Indian J Pharmacol 2012; 44: 407\u2013411.","journal-title":"Indian J Pharmacol"},{"key":"BFjhh20178_CR25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/VHRM.S3056","volume":"5","author":"E Agabiti-Rosei","year":"2009","unstructured":"Agabiti-Rosei E, Porteri E, Rizzoni D . Arterial stiffness, hypertension, and rational use of nebivolol. Vasc Health Risk Manag 2009; 5: 353\u2013360.","journal-title":"Vasc Health Risk Manag"},{"key":"BFjhh20178_CR26","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2143\/AC.59.4.2005202","volume":"59","author":"A Persu","year":"2004","unstructured":"Persu A, De Plaen J-F . Recent insights in the development of organ damage caused by hypertension. Acta Cardiol 2004; 59: 369\u2013381.","journal-title":"Acta Cardiol"},{"key":"BFjhh20178_CR27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/jhh.2013.55","volume":"28","author":"S Mennuni","year":"2014","unstructured":"Mennuni S, Rubattu S, Pierelli G, Tocci G, Fofi C, Volpe M . Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. J Hum Hypertens 2014; 28: 74\u201379.","journal-title":"J Hum Hypertens"},{"key":"BFjhh20178_CR28","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.lfs.2009.07.006","volume":"85","author":"S Gschwend","year":"2009","unstructured":"Gschwend S, Haug MB, Nierhaus M, Schulz A, Vetter R, Kossmehl P et al. Short-term treatment with a beta-blocker with vasodilative capacities improves intrarenal endothelial function in experimental renal failure. Life Sci 2009; 85: 431\u2013437.","journal-title":"Life Sci"},{"key":"BFjhh20178_CR29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/0167-5273(92)90238-X","volume":"35","author":"TY Chan","year":"1992","unstructured":"Chan TY, Woo KS, Nicholls MG . The application of nebivolol in essential hypertension: a double-blind, randomized, placebo-controlled study. Int J Cardiol 1992; 35: 387\u2013395.","journal-title":"Int J Cardiol"},{"key":"BFjhh20178_CR30","doi-asserted-by":"publisher","first-page":"c213","DOI":"10.1159\/000262304","volume":"114","author":"M Duranay","year":"2010","unstructured":"Duranay M, Kanbay M, Akay H, Unverdi S, S\u00fcrer H, Altay M et al. Nebivolol improves renal function in patients who underwent angioplasty due to renal artery stenosis: a pilot study. Nephron Clin Pract 2010; 114: c213\u2013c217.","journal-title":"Nephron Clin Pract"},{"key":"BFjhh20178_CR31","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/clc.21013","volume":"35","author":"O G\u00fcnebakmaz","year":"2012","unstructured":"G\u00fcnebakmaz O, Kaya MG, Koc F, Akpek M, Kasapkara A, Inanc MT et al. Does nebivolol prevent contrast-induced nephropathy in humans? Clin Cardiol 2012; 35: 250\u2013254.","journal-title":"Clin Cardiol"},{"key":"BFjhh20178_CR32","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution. Eur J Heart Fail 2016; 18: 891\u2013975.","journal-title":"Eur J Heart Fail"},{"key":"BFjhh20178_CR33","first-page":"169","volume":"4","author":"S Gonz\u00e1lez-Garc\u00eda","year":"2014","unstructured":"Gonz\u00e1lez-Garc\u00eda S, Hern\u00e1ndez-D\u00edaz Z, Quevedo-Sotolongo L, Pe\u00f1a-S\u00e1nchez M, Pino-Pe\u00f1a Y, Fern\u00e1ndez-Carriera R et al. Resistive cerebral blood flow as a potential marker of subclinical brain damage in essential hypertension. World J CVD 2014; 4: 169\u2013178.","journal-title":"World J CVD"},{"key":"BFjhh20178_CR34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.pharmthera.2005.09.002","volume":"111","author":"G Cohuet","year":"2006","unstructured":"Cohuet G, Struijker-Boudier H . Mechanisms of target organ damage caused by hypertension: therapeutic potential. Pharmacol Ther 2006; 111: 81\u201398.","journal-title":"Pharmacol Ther"},{"key":"BFjhh20178_CR35","unstructured":"Gonz\u00e1lez-Quevedo A, Garc\u00eda SG, Concepci\u00f3n OF, Freixas RS, Sotolongo LQ, S\u00e1nchez MP et al. Demonstration of subclinical organ damage to the central nervous system in essential hypertension. In: Gonzalez-Quevedo A (eds). Brain Damage\u2014Bridging Between Basic Research and Clinics. InTech: Rijeka, Croatia, 2012, pp 79\u201398.."},{"key":"BFjhh20178_CR36","doi-asserted-by":"publisher","first-page":"H1418","DOI":"10.1152\/ajpcell.1995.268.6.C1418","volume":"268","author":"T Ohtsuki","year":"1995","unstructured":"Ohtsuki T, Matsumoto M, Suzuki K, Taniguchi N, Kamada T . Mitochondrial lipid peroxidation and superoxide dismutase in rat hypertensive target organs. Am J Physiol 1995; 268: H1418\u2013H1421.","journal-title":"Am J Physiol"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/jhh20178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/jhh20178","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/jhh.2017.8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/jhh20178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:36:59Z","timestamp":1684431419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/jhh20178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,2]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["BFjhh20178"],"URL":"https:\/\/doi.org\/10.1038\/jhh.2017.8","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,2]]},"assertion":[{"value":"18 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This publication was sponsored by A Menarini Asia Pacific Pte Ltd. Clinical authors have received an honorarium for the development and manuscript writing.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}